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Background: Limited data exists on the burden and features of non-cirrhotic hepatocellular 
carcinoma (HCC) in the United States. 
Aims: To evaluate characteristics, etiologies, trends, and outcomes of non-cirrhotic HCC from 
2000 to 2014 at 5 large US centers. Methods: Patient, tumor and liver disease etiology data 
were manually collected. The presence of underlying cirrhosis was assessed based on 
published criteria.   
Results: Of 5,144 eligible patients with HCC, 11.7% had no underlying cirrhosis. Non-cirrhotic 
patients were older (64.1 vs 61.2 years), more frequently females (33.9% vs 20.8%), and less 
frequently Black (8.3% vs. 12.4%) (p<0.001 for all). Among non-cirrhotic patients, non-alcoholic 
fatty liver disease (NAFLD) was the most common liver disease (26.3%), followed by hepatitis C 
(HCV) (12.1%), and hepatitis B (10%). As of 2014, there was increased percentage of cirrhotic 
HCC and a decline in non-cirrhotic HCC mainly due to significant annual increases in cirrhotic 
HCC due to HCV [0.96% (p<0.0001)] and NAFLD [0.66% (p=0.003)]. Patients with non-cirrhotic 
HCC had larger tumors (8.9 vs 5.3 cm), were less frequently within Milan criteria (15% vs 39%), 
more frequently underwent resection (43.6% vs 8%) (p<0.001 for all), and had better overall 
survival than cirrhotic HCC patients (median 1.8 vs 1.3 years, p=0.004).  
Conclusions: Nearly 12% of HCCs occurred in patients without underlying cirrhosis, and 
NAFLD was the most common liver disease in these patients. During the study period, the 
frequency of non-cirrhotic HCC decreased whereas that of cirrhotic HCC increased. Although 
non-cirrhotic patients presented with more advanced HCC, their survival was better.  







Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide, 
causing more than 700,000 deaths per year1. HCC incidence rates have significantly increased 
in the United States (US), surpassed only by thyroid cancer2-5. Further, HCC mortality rate is the 
highest of all cancers in the US4. 
While viral hepatitis and alcohol have traditionally been the main liver diseases driving the 
occurrence of HCC6,7, the new millennium has witnessed the emergence of non-alcoholic fatty 
liver disease (NAFLD) as a major contributor to the burden of HCC, not only in the US and 
Western countries but also at the global level8-11. Over the past 2 decades, NAFLD cirrhosis has 
been increasingly recognized as an important cause of HCC12-18. Recent studies based on 
national data have shown a significant and recent increase in NAFLD contribution to the HCC 
burden and mortality in the US8,10,19,20. In a study of United Network for Organ Sharing (UNOS) 
registry from 2002-2012, liver transplantation for HCC related to NAFLD has increased 4-folds 
compared to a two-fold  increase for HCC related to hepatitis C virus (HCV), making NAFLD the 
most rapidly growing indication for liver transplantation for HCC in the US19. Between 2001-
2013, HCV followed by NAFLD were the major contributors to rising rates of cirrhosis and HCC 
among US Veterans10.  In a study of the Surveillance, Epidemiology and End Results (SEER) 
registries with Medicare-linkage files for HCC between 2004-2009, a 9% annual increase in 
NAFLD related HCC was observed, exceeded only by a 13% annual increase in HCV related 
HCC. However, whether NAFLD contribution to the expanding HCC burden is exclusively via 
the cirrhosis-carcinogenesis pathway was not clear from these studies.  
The development of HCC in a non-cirrhotic setting has long been recognized as an uncommon 
event in patients with chronic liver disease, occurring primarily in the setting of hepatitis B virus 
(HBV) infection 21,22. Accumulating data from different case reports and studies over the past 2 
decades have shown the same phenomenon occurs in the setting of non-cirrhotic NAFLD23-28. 
The mechanisms of carcinogenesis in the setting of non-cirrhotic NAFLD are not entirely clear, 
but the chronic inflammatory state associated with obesity and commonly seen with NAFLD, 
 
 
insulin resistance and lipotoxicity may alter hepatocyte proliferation and different modes of 
hepatocyte death, thus promoting a carcinogenic milieu29-32.  
There seems to be geographical differences in the frequency of non-cirrhotic HCC in the setting 
of NAFLD; only 15% of patients with NAFLD and HCC were not cirrhotic in an Australian 
study33, compared to 27% in a single center US study34, and up to 50% in European and 
Japanese studies35-38. However, beside population differences, some of these studies were 
based on data from single centers, had small study size, lacked specific criteria to define the 
non-cirrhotic status, or included only patients referred for surgical resection. The proportion of 
non-cirrhotic HCC in the US has not been adequately quantified.  
While the trends of HCC related to specific underlying liver diseases in select populations in the 
US have been recently described based on the UNOS, Veterans Administration (VA), and 
SEER databases, these studies relied on International Classification of Diseases (ICD) codes 
for identifying underlying liver diseases or presence of obesity or diabetes to infer the presence 
of NAFLD8,10,19. No other large-scale data with direct ascertainment of the underlying etiology of 
liver disease and cirrhotic status is yet available in the US to allow for high-resolution evaluation 
of all comers with HCC. With the limitations in current literature39, it is unclear whether the rising 
incidence of NAFLD in the US has resulted in higher number of non-cirrhotic HCC. If this were 
true, it would have a major public health impact as the proportion of HCC linked to NAFLD is 
anticipated to be on the rise with the global and growing epidemic of obesity and metabolic 
syndrome.  
To address these questions, we studied 5,144 patients with HCC seen at 5 major liver centers 
across the United States (US) over a 14.5 year period between 2000-2014. The primary 
objectives of this study were to 1) characterize the frequency and characteristics of non-cirrhotic 
HCC, 2) assess the trends of percentage of non-cirrhotic HCC over the study period, and 3) 
determine the contribution of NAFLD to the burden of non-cirrhotic HCC. As secondary 
 
 
objectives, we report on the treatment modalities these patients received and their survival 
compared to cirrhotic patients with HCC.  
 
METHODS 
HCC case identification and characterization 
Using the institutional Cancer Registry at each participating site, all adult patients 18 years of 
age or older  with HCC seen at the study centers ( Indiana University School of Medicine, 
Indianapolis, IN; MD Anderson Cancer Center, Houston, Texas, MD, Vanderbilt University 
School of Medicine, Nashville, Tennessee; Atrium Health, Charlotte, NC,  Columbia University 
Vagelos College of Physicians and Surgeons, New York, NY) and their affiliate hospitals from 
January 2000 to June 2014 were identified. We performed manual chart review of each 
identified case to verify the diagnosis and extract the data. The data were managed centrally by 
the data coordinating center at Indiana University. The study was reviewed and approved by 
each participating site’s Institutional Review Board. 
The diagnosis of HCC required histological and/or radiographic evidence consistent with the 
American Association for Study of Liver Disease (AASLD) guidelines40,41. Histology was most 
often confirmed at the time of resection, transplantation, or death and not as the primary 
diagnostic modality for HCC across centers. Patients were excluded from this study if they had 
1) uncertain HCC diagnosis; 2) fibrolamellar HCC; 3) cholangiocarcinoma; 4) tumor recurrence 
as the reason for referral to our institution; and 5) insufficient data in the medical records.  
Demographics, comorbidities, clinical data and laboratory values and tumor characteristics were 
collected at the time of HCC diagnosis. For the tumor size, the largest tumor diameter was 
recorded for each patient. The presence of macrovascular invasion or distant metastases, TNM 
staging and whether the HCC was within Milan criteria were captured42,43. Although the Milan 
criteria were originally developed in patients with cirrhosis, these criteria are now universally 
known and provide easy summary of tumor burden in terms of size and number of lesions, 
 
 
therefore were used to define the HCC burden in non-cirrhotic patients in this study. All 
treatment modalities received throughout the disease course were manually extracted from 
medical records.  
Determination of comorbidities and underlying liver disease 
Physicians’ documentation and/or presence of confirmatory laboratory tests were used to 
assess for the presence of the following medical co-morbidities: diabetes mellitus, hypertension, 
dyslipidemia, coronary artery disease, and peripheral vascular disease, as well as the following 
underlying liver disease etiologies: HCV, HBV, alcohol, autoimmune hepatitis, primary biliary 
cholangitis, primary sclerosing cholangitis, hemochromatosis, and alpha-1-antitrypsin 
deficiency. Alcohol abuse was defined as history of more than 3 drinks a day, clinical 
documentation of alcoholism/alcohol abuse, enrollment in a substance abuse treatment 
program, or history of alcoholic hepatitis44. NAFLD diagnosis required either a diagnosis 
assigned by the managing hepatologist and/or evidence of hepatic steatosis, either by imaging 
or by histology in the absence of an alternative liver disease 45. The rare liver disease category 
included diseases like amyloidosis, sarcoidosis, cardiac cirrhosis, drug-induced chronic liver 
disease, and environmental exposure. Patients were classified as having unclear or unknown 
etiology of liver disease if, after extensive chart review, there was sufficient information to make 
a diagnosis of underlying etiology of disease, but no clear underlying etiology was found or if 
there was not sufficient data to make a diagnosis. 
Definition of the cirrhotic and non-cirrhotic status 
Patients were classified into 4 cirrhosis categories according to criteria published by Mittal et 
al44: 1) level 1 evidence (very high probability) of no cirrhosis, which requires histology and 
imaging evidence; 2) level 2 evidence (high probability) of no cirrhosis, which lacks histology but 
is based on imaging and laboratory criteria; 3) confirmed cirrhosis, which is based on 
histological, imaging, clinical or laboratory criteria; or 4) unclassified if there was insufficient data 
to classify into any of the above cirrhosis categories. The AST to Platelet Ratio Index (APRI) 
 
 
Fibrosis-4 (FIB-4), and Model for End-Stage Liver Disease (MELD) were calculated for all 
patients using the formulas published and validated in the original papers46-49. Presence or 
absence of liver-related complications (ascites, hepatic encephalopathy, varices, spontaneous 
bacterial peritonitis, renal failure, portal vein thrombosis and hepatic hydrothorax) was collected 
starting the time of HCC diagnosis until the last documentation available in medical records. 
Validation of Mittal’s level 2 (high probability) criteria for absence of cirrhosis 
The Mittal criteria were constructed to increase confidence in the cirrhotic or non-cirrhotic status 
assignment of the subgroup of patients who lacked liver histology for confirmation (Table 1) 44. 
While the criteria for confirmed cirrhosis and level 1 evidence (very high probability) for absence 
of cirrhosis are clinically sound, the performance of their proposed criteria for level 2 evidence 
(high probability) of absence of cirrhosis has not been validated. The level 2 criteria for “no 
cirrhosis” consist of APRI <1 based on laboratory results available nearest to HCC diagnosis 
within 6 months before and 4 weeks after HCC diagnosis; in addition to no features suggestive 
of cirrhosis on abdominal imaging performed nearest to HCC diagnosis within 3 years before 
HCC diagnosis; and 2 of 3 test values in normal range based on laboratory results available 
nearest to HCC diagnosis within 6 months before and 4 weeks after HCC diagnosis [albumin 
>3.5 g/L, platelets 200,000/mL, or international normalized ratio (INR) <1.1]. By adding imaging 
and laboratory criteria for absence of cirrhosis to APRI, the aim was to enhance the specificity of 
these criteria and thus reducing the risk of misclassification when identifying non-cirrhotic status 
in the absence of liver histology. 
To validate the level 2 Mittal criteria for the absence of cirrhosis, we randomly selected 200 
patients from a large database of 1020 patients who underwent liver biopsy as part of their 
clinical care at Indiana University. Patients had different underlying liver disease etiologies; 100 
had histologically proven cirrhosis and 100 had no histological evidence cirrhosis (16 patients 
with fibrosis stage 0, 29 patients with fibrosis stage 1, 34 patients with fibrosis stage 2, and 21 
patients with fibrosis stage 3). Applicability of level 2 non cirrhosis criteria was assessed after 
 
 
collection of laboratory data, imaging findings and evidence of complications. The area under 
the receiver operating characteristic curve (AUROC), sensitivity, specificity, positive predictive 
value (PPV), and negative predictive value (NPV) were computed for the level 2 no-cirrhosis 
criteria, using liver biopsy as the reference test. The performance parameters of level 2 Mittal 
criteria for identifying non-cirrhotic status were: AUROC 0.80 (95% CI: 0.74-0.86), sensitivity 
62.0%, specificity 98.0%, PPV 96.9%, and NPV 72.0%.   
Survival status 
Patient survival was ascertained from Cancer Registries and medical records. For patients who 
are still alive or died with an unknown date of death, the date of last contact available in the 
medical record was used to define the time of censoring for the survival analysis.  
Statistical Methods  
Categorical variables were summarized and compared using chi-square test. Continuous 
variables were summarized and compared using ANOVA and t-test. Simple linear regression 
was used to evaluate the annual trends in terms of percentage of respective non-cirrhotic HCC, 
NAFLD, HBV, HCV, or alcohol etiology over the year. A sensitivity analysis was performed  for 
the sub-cohort when patients who had level 2 no cirrhosis were excluded. HCV was considered 
the primary etiology of liver disease regardless  of  other etiology, i.e., it could be either HCV 
and Alcohol, HCV and HBV with or without alcohol, or HCV alone; HBV was considered the 
primary etiology of liver disease if no HCV was presented, i.e., HBV and Alcohol, or HBV alone. 
Overall survival time was defined from the date of HCC diagnosis to the date of death, censored 
at the date of last contact. The overall survival probability was estimated by the Kaplan-Meier 
method and compared between groups using the log-rank test. A Cox proportional hazards 
regression model was used to evaluate the association between the risk factors and the overall 
survival. The following risk factors were considered for the Cox model: patient demographics 
[age, body mass index (BMI), sex, and race], medical history and comorbid conditions (date of 
HCC diagnosis, diabetes, hypertension, dyslipidemia, coronary artery disease, and peripheral 
 
 
vascular disease), laboratory values [alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), total bilirubin, alkaline phosphatase, albumin, platelets, creatinine, INR, 
and alpha fetoprotein (AFP)], tumor characteristics (tumor size and anatomic stage), treatment 
modalities (resection, liver transplantation, catheter delivered therapy, sorafenib, stereotactic 
body radiation therapy (SBRT), radiofrequency ablation (RFA), microwave ablation, 
palliative/hospice care, other, none, and unknown), and underlying etiology (HCV, HBV, alcohol, 
NAFLD, and unknown/unclear). Variables that were significant at p<0.10 in the univariate 
analysis were included in a stepwise selection procedure to select which variables would be 
included in the final Cox multivariate regression model. Variables of clinical significance 
including age, BMI, sex, race, platelets, diabetes, and underlying etiology were always retained 
in the model. P-value <0.05 was considered statistically significant. All analyses were performed 
using SAS version 9.4 (SAS Institute; Cary, NC). 
 
RESULTS 
Prevalence of non-cirrhotic HCC in the study cohort 
The study flow diagram is shown in Supplementary Figure 1. Of 6,250 identified patients, 
5,144 met the inclusion criteria for HCC and had classifiable cirrhotic status; of whom 11.7% 
had no evidence of cirrhosis (7.7% by level 1 and 4% by level 2 criteria) and 88.2% had 
confirmed cirrhosis. There were no differences between level 1 and 2 “no-cirrhosis” patients in 
terms of their age, sex, race, BMI, frequency of obesity, diabetes, other comorbidities or 
frequency of alcohol abuse (Supplementary Table 1). The majority of HCC occurred in a 
cirrhotic background for all specific liver diseases, including HBV and NAFLD (Table 2).  
Characteristics of patients with non-cirrhotic HCC 
Non-cirrhotic patients (level 1 or 2 no cirrhosis, combined) were older (64.1 ± 14.0 vs 61.2 ± 9.9 
years, p <0.001), more frequently females (34% vs 21%, p <.001) and Asian (8% vs 3%, p 
<0.001) but less frequently Black (8% vs 12%, p <0.001), compared to cirrhotic patients with 
 
 
HCC (Table 2). They had lower frequency of obesity (22.1% vs 30.7%, p<0.001), diabetes 
(34.1% vs 38.7%, p=0.02) and alcohol abuse (17.1% vs 46.2%, p<0.001), but higher frequency 
of hypertension (68.4% vs 61.5%, p=0.001), dyslipidemia (38.0% vs 22.0%, p<0.001), coronary 
artery disease (22.0% vs 16.7%, p=0.001), and peripheral vascular disease (11.5% vs 7.4%, 
p<0.001). As expected, non-cirrhotic patients had higher albumin (3.9 ± 0.6 vs 3.3 ± 0.7 g/dL, 
p<0.001) and platelet count (278.9 ± 118.9 vs 148.4 ± 101.4 K/mm3, p<0.001) but lower serum 
total bilirubin (1.0 ± 2.0 vs 2.2 ± 3.3 mg/dL, p<0.001), INR  (1.1 ± 0.2 vs 1.3 ± 0.4, p<0.001), 
APRI (1.0 ± 1.8 vs 3.1 ± 6.6, p<0.001) and MELD scores (8.9 ± 3.4 vs 12.2 ± 5.6, p<0.001) and 
better performance status than cirrhotic patients with HCC (Table 2).  
Trends of non-cirrhotic HCC over the study period 
From January 2000 to June 2014, the percentage of non-cirrhotic HCC cases declined, whereas 
the percentage of cirrhotic HCC cases increased (p<0.001; Figure 1). The same trend was 
observed when only level 1 no cirrhosis patients were included in this analysis (p<0.001; 
Supplementary Figure 2). We also analyzed the trends of cirrhotic and non-cirrhotic HCC 
evaluated per underlying liver disease etiology (Figure 2). From 2000 to 2014, there were no 
statistically significant changes in the HCV frequency (annual increase 0.37%, p=0.28) and 
NAFLD frequency (annual increase 0.76%, p=0.12) among non-cirrhotic HCC. In contrast, the 
increases were statistically significant among cirrhotic HCC (annual increase 0.96% for HCV 
frequency, p<0.0001, and 0.66% for NAFLD frequency, p=0.003). Overall, there was an annual 
0.74% net reduction in non-cirrhotic HCC frequency (p<0.001).  Cirrhotic and non-cirrhotic HCC 
burdens contributed by alcohol and HBV showed only significant decline for cirrhotic HCC 
related to HBV (Figure 2). 
Etiology of liver disease in non-cirrhotic HCC   
Among all HCC patients in the study cohort (Table 2), HCV was the most common liver disease 
associated with HCC (49%), followed by NAFLD (14.9%), alcohol (12.7%) and HBV (7.4%). 
 
 
About 12.5% of the study cohort had the underlying liver disease status documented as unclear 
or unknown. 
Among non-cirrhotic HCC patients, NAFLD was the most common liver disease occurring in 
26.3% of patients, followed by HCV in 12.1%, HBV in 10%, then alcohol in 7.3% of the patients.  
In cirrhotic HCC patients, HCV was the most common liver disease associated with HCC 
(53.8%), followed by alcohol (13.5%), NAFLD (13.4%), and HBV (7.1%).  
Tumor Characteristics in patients with non-cirrhotic HCC  
Non-cirrhotic patients had significantly larger tumors (8.9 ± 4.8 vs 5.3 ± 3.9 cm, p<0.001), more 
frequently had HCC diagnosed incidentally (18.9% vs 11.2%, p<0.001) or for symptoms work-
up (60.2% vs 55.3%, p=0.03) and less frequently as part of surveillance (16.9% vs 29.1%, 
p<0.001) than cirrhotic patients (Table 3). They more frequently had histological confirmation of 
HCC (90.6% vs 62.3%, p<0.001). HCC in non-cirrhotic patients was more advanced (stage III or 
IV) (52.3% vs 45.5%, p=0.002) and more frequently presented as single (37.0% vs 34.4%, 
p<0.001) or large multinodular lesions (24.7% vs 21.5%, p<0.001) with vascular invasion or 
extrahepatic spread (36.3% vs 33.5%, p<0.001). Consequently, these patients less frequently 
presented within the Milan Criteria (14.9% vs 39.2%, p<0.001) than cirrhotic patients.  
Treatment and survival of patients with non-cirrhotic HCC 
Patients with non-cirrhotic HCC more frequently underwent surgical resection (43.6% vs 8.0%, 
p<0.001) but less frequently received liver transplantation (2.8% vs 19.2%, p<0.001), catheter 
delivered therapies (35.7% vs 42.7%, p=0.001) or palliative care-hospice services (16.5% vs 
26.8%, p<0.001) compared to patients with cirrhotic HCC (Table 4). Patients with non-cirrhotic 
HCC had better median overall survival than patients with cirrhotic HCC [1.80 years (95% CI: 
1.56-2.09) vs 1.32 years (95% CI: 1.25-1.39), p=0.004]. Non-cirrhotic patient’s overall survival 
was significantly higher at 1 (63.5% vs 56.3%, p<0.001) and 3 years (35.2% vs 30.3%,p= 0.02) 
but not different at 5 years from diagnosis (25.7% vs 23.4%, p= 0.26) compared to patients with 
cirrhotic HCC (Table 5 and Figure 3).  
 
 
Risk factors associated with increased mortality in patients with non-cirrhotic HCC were INR 
(HR 1.96, 95% CI 1.21–3.18, p=0.006), AFP (HR 1.00, 95% CI 1.00–1.00, p<0.001), anatomic 
stage of HCC [ stage III vs stage I (HR 2.01, 95% CI 1.22–2.81, p<0.001, and stage IV vs stage I; 
HR 2.12, 95% CI 1.45–3.10, p<0.001), and hospice care (HR 1.85, 95% CI 1.35-2.54, p<.001), 
whereas albumin (HR 0.65, 95% CI 0.51-0.83, p<.001), surgical resection (HR 0.24, 95% CI 
0.17–0.34, p<.001) and liver transplantation (HR 0.16, 95% CI 0.05–0.53, p=0.002) were 
associated with reduced risk of death (Table 6). The etiology of underlying liver disease did not 
affect mortality in patients with non-cirrhotic HCC. 
 
DISCUSSION 
In this large US multicenter study, HCC arose in non-cirrhotic liver background in nearly 12% of 
patients. NAFLD was the most common liver disease in these patients followed by HCV. NAFLD 
has contributed to both non-cirrhotic and cirrhotic HCC burden over the 14.5 year study period. 
However, the net effect in the cohort as of the year 2014 was increased percentage of cirrhotic 
HCC and a decline in non-cirrhotic HCC.   
While this study and others from the US and UK have shown that NAFLD is a rapidly increasing 
cause of HCC8,9,19, it was not previously investigated whether NAFLD contribution is mainly 
through the cirrhosis-carcinogenesis pathway and/or non-cirrhotic-carcinogenesis pathway. Our 
study shows that NAFLD is contributing to the enlarging HCC burden via both the non-cirrhotic 
and cirrhotic pathways. The majority of HCC contributed by NAFLD and HCV were via the 
cirrhosis-HCC pathway, thus explaining the overall rise in cirrhotic HCC. The observed increase 
in the percentage of non-cirrhotic HCC related to NAFLD was not significant or large enough to 
result in increasing the total burden of non-cirrhotic HCC. This is possibly because the 
contribution of other liver diseases to the non-cirrhotic HCC burden was not large enough and 
the fraction contributed by NAFLD was not substantial as of the year 2014.  
 
 
NAFLD (and HBV as expected) were the only etiologies significantly more common in non-
cirrhotic HCC. Indeed, patients with non-cirrhotic HCC were twice as likely to have NAFLD than 
patients with cirrhotic HCC (26.3% vs 13.4%, p <0.001), highlighting the importance of further 
investigating the mechanisms of HCC development in the absence of cirrhosis in patients with 
NAFLD. This finding is consistent with the findings of a recent systematic analysis showing that 
in the absence of cirrhosis, patients with NASH have a higher risk of HCC than patients with 
other liver diseases50. 
With the advent of effective cures, US national predictions project a decline in the contribution of 
HCV to the cirrhosis and HCC burdens and liver transplant utilization coinciding with a rise in 
NAFLD impact on these burdens and resources19,20,51,52.  Thus, in this context, the observed 
significant rise in cirrhotic NAFLD HCC in this study is an important finding that confirms current 
AASLD guideline recommendations of surveillance for HCC in patients with NAFLD cirrhosis40. 
Our observation of a rise in the percentage of non-cirrhotic HCC cases related to NAFLD, albeit 
not statistically significant as of the end of study in 2014, will require further follow up study of 
the trend in the setting of the ongoing epidemic of obesity and NAFLD.  
The non-cirrhotic HCC group included significantly more women than the cirrhotic HCC group, a 
finding seen in another study53. The reason for this disparity is unclear but may be related to a 
higher prevalence of NAFLD observed in women compared to men in this study (23.3% vs 
12.4%, p<0.001).  
The proportion of Asians patients was also higher in the non-cirrhotic group, probably due to 
higher proportion of HBV which was the underlying disease in 73.9% in non-cirrhotic Asian 
patients compared to 60% in cirrhotic Asian patients(p=0.8).  
Similar to the findings of the Mittal et al study44, slightly higher proportion of HCV patients had 
non-cirrhotic HCC (12.1%) vs those with HBV (10%). While HBV is more carcinogenic than 
HCV, the prevalence and time of acquisition of HBV (at birth or childhood in endemic areas in 
Asia and Africa vs adulthood in the Western countries) may be the reason for this observation.  
 
 
The overall rate of non-cirrhotic HCC in this study (11.7%) is within the range of reported rates 
from prior US and European studies (6.9%-27.8%)9,44,53,54. The overall rate of non-cirrhotic HCC 
related to NAFLD (20.7%) was close to that reported in recent UK (22.8%)9 and German 
(22.2%)55 studies but lower than other studies reporting these rates by disease etiology34-38. 
These differences may be due to population differences and varying criteria for ascertaining the 
cirrhotic status between studies. We used the Mittal criteria to determine cirrhotic status after we 
validated the Mittal level 2 criteria for absence of cirrhosis in an independent cohort and found 
them to be highly specific (specificity of 98%). This should facilitate other investigators to define 
the absence of cirrhosis in their cohort studies with high confidence. 
 
Non-cirrhotic patients with HCC presented at older age and with larger and more advanced 
HCC that was more commonly outside the Milan criteria, finding confirming those noted in other 
studies 53,56,57. The significant difference in tumor size is probably due to lack of HCC 
surveillance in the majority of patients with non-cirrhotic HCC, who were not known to have 
underlying liver disease prior to the HCC presentation. Regular HCC surveillance within 2 years 
prior to HCC diagnosis was documented in 14.7% of non-cirrhotic patients, which is higher than 
the proportion of HBV patients (10%) in this group, reflecting variability in practice patterns and 
adherence to guidelines. The reason for imbalance between cirrhotic and non-cirrhotic patients 
in frequency of metabolic and vascular comorbidities (non-cirrhotics with lower frequency of 
obesity and diabetes but higher frequency of hypertension, dyslipidemia and coronary artery 
disease), is unclear. Similar to the findings in Weinmann et al study55, patients with NAFLD and 
non-cirrhotic HCC in our cohort were older, more frequently females, had a higher BMI and 
higher frequency of metabolic and coronary artery disease (data not shown). 
Non-cirrhotic patients more frequently underwent resection than liver transplantation and had 
better median overall survival than cirrhotic HCC. The median overall survival of non-cirrhotic 
patients was better than cirrhotic patients despite presenting with more advanced tumors, 
 
 
probably due to normal underlying liver function, lack of portal hypertension associated with 
cirrhosis and better performance status at presentation. Nevertheless, the prognosis for all 
patients with HCC, with or without cirrhosis, remains poor in the US at the present. 
While etiology of liver disease did not affect mortality in the non-cirrhotic patients, INR, albumin, 
AFP, anatomic stage of HCC, hospice care, surgical resection and liver transplantation 
influenced the risk of death in our study. Unlike findings of a prior single center study that 
assessed 143 patients with non-cirrhotic HCC specifically referred for  surgical resection, age or 
sex did not influence the risk of death in our study58.  
 
This study has several limitations. As with any retrospective study, some data points were 
missing (e.g. on performance status or histology), but our manual review of each individual 
patient’s chart significantly reduced missing data points and allowed collection of meaningful 
data to permit high resolution examination of these patients and their tumors characteristics. 
The higher rate of unclear or unknown underlying liver etiology in non-cirrhotic patients may hint 
at less frequent hepatology evaluation of the underlying liver disease etiology prior to resection 
and locoregional therapies in this group.  Another limitation is that beyond the presence or 
absence of cirrhotic background in the resection sample, the exact stage of fibrosis was not 
consistently given in the pathology reports and we failed to systematically collect such data 
when available. However, we augmented the our data by the use of APRI and FIB4 score, 
which both show that the majority of patients fell below the cirrhotic range for these tests. 
Similar to other studies, there is referral bias in this study as these patients were seen at tertiary 
care centers. Although our findings may be applicable to HCC patients seen in other tertiary 
centers in the US, they may not be generalizable to HCC patients seen in the community. The 
reliance on non-histological criteria to determine the absence of cirrhosis in a small subset (4%) 
may have resulted in misclassification. However, we validated the performance of the level 2 
Mittal criteria for absence of cirrhosis in an independent cohort and found these criteria to be 
 
 
highly specific. Further, when we excluded level 2 no cirrhosis patients from the analysis, the 
trends of cirrhotic and non-cirrhotic HCC remained the same, thus increasing the confidence in 
our observation. 
Despite these limitations, this study has several strengths. It included the largest number of 
patients with non-cirrhotic HCC in the literature to date. We validated and systematically applied 
specific criteria to determine the cirrhotic status. The manual review of each participant’s chart 
allowed us to collect extensive data to phenotype the patients and tumors. We did not use ICD 
codes or presence of comorbidities to infer the presence of NAFLD, rather we directly verified 
the etiology of underlying liver disease including NAFLD based on manual chart reviews. Unlike 
other large cohorts with a primary focus on transplantation or resection, our dataset includes 
four liver transplant centers and one national cancer center each offering a range of treatment 
modalities. Finally, the study period from 2000-2014 allowed us to assess the trends of non-
cirrhotic HCC and its associated liver diseases.   
 
In conclusion, non-cirrhotic HCC account for nearly 12% of all HCC cases in this large 
multicenter US study. NAFLD was the most common liver disease in non-cirrhotic HCC, and a 
leading cause of cirrhotic HCC in this population. Although NAFLD is contributing to the rising 
HCC burden via both the non-cirrhotic and cirrhotic stages, its contribution to non-cirrhotic HCC 
burden was not significant or large enough to result in increasing the total burden of non-
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Figure 1:  
Panel A:  Non-cirrhotic HCC: Percentage of non-cirrhotic patients from 2000 to 2014  
Panel B:  Cirrhotic HCC: Percentage of cirrhotic patients from 2000 to 2014  
 
Figure 2:  
 
Time Trends of the Percentage of Non-Cirrhotic and Cirrhotic HCC per Underlying Liver 
Disease Etiology  
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Table 1. Mittal’s definitions for classification of cirrhosis categories 
Cirrhosis Category Definition 
Level 1 evidence of no 
cirrhosis (very high 
probability) 
No evidence of cirrhosis on resection specimen or liver biopsy performed 
within 1 year before or at time of HCC diagnosis. 
AND 
No features suggestive of cirrhosis on abdominal imaging available 
nearest to HCC diagnosis within 3 years before HCC diagnosis. 
 
Level 2 evidence of no 
cirrhosis (high 
probability) 
APRI <1 based on laboratory results available nearest to HCC diagnosis 
within 6 months before and 4 weeks after HCC diagnosis. 
AND 
No features suggestive of cirrhosis on abdominal imaging performed 
nearest to HCC diagnosis within 3 years before HCC diagnosis. 
AND 
Two of 3 test values in normal range based on laboratory results 
available nearest to HCC diagnosis within 6 months before and 4 weeks 
after HCC diagnosis (albumin >3.5 g/L, platelets >200,000/mL, or 
international normalized ratio <1.1). 
 
Confirmed Cirrhosis Documented cirrhosis on resection specimen or liver biopsy performed 
any time before or at time of HCC diagnosis. 
OR 
Features suggestive of cirrhosis on abdominal imaging performed 
nearest to HCC diagnosis within 3 years before HCC diagnosis. 
OR 
Documented presence of ascites, varices, or hepatic encephalopathy. 
OR 
Abnormal values on 2 of 3 laboratory tests available nearest to HCC 
diagnosis within 6 months before and 4 weeks after HCC diagnosis 
(albumin <3.0 g/L, platelets <200,000 mL, international normalized ratio 
>1.1). 
 
Unclassified Insufficient information to classify in any cirrhosis category. 












Table 2:  Characteristics of the patients with hepatocellular carcinoma with and without 
underlying cirrhosis 
 






Age (Years)  64.1 ± 14.0   61.2 ± 9.9  <0.001 
Male Sex 400 (66.1%) 3,597 (79.2%) <0.001 
Race 
- White 420 (70.0%) 3,149 (70.4%) 
<0.001 
- Black 50 (8.3%) 556 (12.4%) 
- Hispanic 59 (9.8%) 452 (10.1%) 
- Asian 46 (7.7%) 140 (3.1%) 
- Other 25 (4.2%) 174 (3.9%) 
Center* 
Atrium Health 55 (9.6%) 509 (89%) 
<0.001 
Columbia 61 (11.3%) 470 (87.2%) 
Indiana University 135 (10.8%) 1054 (84.3%) 
MD Anderson 329 (15.6%) 1728 (82.1%) 
Vanderbilt 25 (2.9%) 778 (90.3%) 
BMI  (kg/m2)  27.3 ± 6.1   28.6 ± 6.0  <0.001 
Obesity 134 (22.1%) 1,392 (30.7%) <0.001 
Diabetes 205 (34.1%) 1,749 (38.7%) 0.02 
Hypertension 412 (68.4%) 2,777 (61.5%) 0.001 
Dyslipidemia 229 (38.0%) 992 (22.0%) <0.001 
Coronary Artery Disease 132 (22.0%) 752 (16.7%) 0.001 
Peripheral Vascular 
Disease 69 (11.5%) 332 (7.4%) <0.001 
History of Alcohol Abuse 102 (17.1%) 2,075 (46.2%) <0.001 
HIV Positive 4 (0.7%) 55 (1.2%) 0.34 
Total Bilirubin (mg/dL)  1.0 ± 2.0   2.2 ± 3.3  <0.001 
Albumin (g/dL)  3.9 ± 0.6   3.3 ± 0.7  <0.001 
Platelets (K/mm3)  278.9 ± 118.9   148.4 ± 101.4  <0.001 
Creatinine (mg/dL)  1.0 ± 0.7   1.1 ± 0.8  0.72 
INR  1.1 ± 0.2   1.3 ± 0.4  <0.001 
MELD Score NA   12.2 ± 5.6   
APRI Score  1.0 ± 1.8   3.1 ± 6.6  <0.001 
APRI Category 
- <1.0 450 (78.5%) 1,077 (25.8%) 
<0.001 - 1.0-2.0 77 (13.4%) 1,143 (27.4%) 
- >2.0 46 (8.0%) 1,950 (46.8%) 
 
 







- <1.60 194 (34.4%) 212 (5.1%) 
<.0001 - 1.60-3.60 255 (45.2%) 874 (21.1%) 
- >3.60 115 (20.4%) 3,066 (73.8%) 
Performance Status 
- 0 (KPS 90 or 100) 190 (49.2%) 799 (38.4%) 
<0.001 
- 1 (KPS 70 or 80) 130 (33.7%) 773 (37.1%) 
- 2 (KPS 50 or 60) 48 (12.4%) 313 (15.0%) 
- 3 (KPS 30 or 40) 16 (4.1%) 164 (7.9%) 
- 4 (KPS 10 or 20) 2 (0.5%) 33 (1.6%) 
Underlying liver disease 
- AIH/PBC/PSC 4 (0.7%) 72 (1.6%) 
<0.001 
- Alcohol alone 44 (7.3%) 611 (13.5%) 
- HBV + Alcohol 10 (1.7%) 59 (1.3%) 
- HBV alone 50 (8.3%) 265 (5.8%) 
- HC/A1ATD 3 (0.5%) 78 (1.7%) 
- HCV + Alcohol 11 (1.8%) 1,053 (23.2%) 
- HCV + HBV (+/- alcohol) 10 (1.7%) 178 (3.9%) 
- HCV alone 52 (8.6%) 1,211 (26.7%) 
- NAFLD 159 (26.3%) 608 (13.4%) 
- Rare etiologies 5 (0.8%) 16 (0.4%) 
- Unclear/Unknown 257 (42.5%) 388 (8.5%) 
 
Abbreviations: BMI: body mass index, HIV: human immunodeficiency virus, INR: international 
normalized ratio, MELD: Model for End-Stage Liver Disease, APRI: AST to Platelet Ratio Index, 
HCV: hepatitis C virus, AIH: autoimmune hepatitis. PBC: primary biliary cholangitis, PSC: 
primary sclerosing cholangitis, HC: hemochromatosis, A1ATD: alpha-1-antitrypsin deficiency, 
NA: not applicable, NAFLD: non-alcoholic fatty liver disease. * Remaining % in each center data 














Tumor Size (cm)  8.9 ± 4.8   5.3 ± 3.9  <.001 
AFP Category 
- <20 242 (45.1%) 1,711 (42.7%) 
0.01 - 20-200 96 (17.9%) 942 (23.5%) 
- >200 199 (37.1%) 1,358 (33.9%) 
- Part of surveillance 84 (16.9%) 1,075 (29.1%) <0.001 
- Incidental 94 (18.9%) 416 (11.2%) <0.001 
- Symptoms work-up 299 (60.2%) 2,045 (55.3%) 0.03 
- Other 4 (0.8%) 6 (0.2%) 0.005 
- NA/Unknown 17 (3.4%) 189 (5.1%) 0.10 
Regular Surveillance within 2 Years before HCC? 
- Yes 73 (14.7%) 1206 (32.5%) 
<0.001 
- Unknown 160 (32.3%) 1432 (38.6%) 
Method of Diagnosis 
- Histology 548 (90.6%) 2828 (62.3%) <.001 
- Imaging 568 (93.9%) 4257 (93.8%) 0.92 
- Other 5 (0.8%) 20 (0.4%) 0.19 
- Unknown 0 (0.0%) 4 (0.1%) 0.46 
Anatomic Stage 
- Stage I 184 (33.6%) 1278 (31.9%) 
<0.001 
- Stage II 77 (14.1%) 905 (22.6%) 
- Stage IIIA 81 (14.8%) 414 (10.3%) 
- Stage IIIB 54 (9.9%) 619 (15.4%) 
- Stage IIIC 16 (2.9%) 44 (1.1%) 
- Stage IVA 31 (5.7%) 210 (5.2%) 
- Stage IVB 104 (19.0%) 537 (13.4%) 
Anatomic Stage Category 
- Stage I or II 261 (47.7%) 2183 (54.5%) 
0.002 
- Stage III or IV 286 (52.3%) 1824 (45.5%) 
Tumor Differentiation 
- Well 139 (29.8%) 757 (33.1%) 
0.056 
- Moderate 206 (44.2%) 1066 (46.6%) 
- Poor 117 (25.1%) 450 (19.7%) 
- Undifferentiated / 











- Single 222 (37.0%) 1545 (34.4%) 
<0.001 
- 3 tumors < 3 cm 12 (2.0%) 478 (10.6%) 
- Large multinodular 148 (24.7%) 966 (21.5%) 
- Vascular invasion or 
extrahepatic spread 218 (36.3%) 1503 (33.5%) 
Tumor within Milan 
Criteria 90 (14.9%) 1774 (39.2%) <0.001 
     
































- Resection 264 (43.6%) 362 (8.0%) <0.001 
- Liver Transplantation 17 (2.8%) 873 (19.2%) <0.001 
- Catheter Delivered 
Therapy 216 (35.7%) 1,939 (42.7%) 0.001 
- Sorafenib 131 (21.7%) 921 (20.3%) 0.43 
- SBRT 54 (8.9%) 348 (7.7%) 0.27 
- RFA and/or Microwave 
Ablation 53 (8.8%) 502 (11.1%) 0.08 
- Palliative/Hospice Care 100 (16.5%) 1,218 (26.8%) <0.001 
- Other 83 (13.7%) 313 (6.9%) <0.001 
- None 19 (3.1%) 246 (5.4%) 0.01 
- Unknown 42 (6.9%) 271 (6.0%) 0.34 
 










































One Year 63.5% 56.3% <.001 
Three Year 35.2% 30.3% 0.02 
Five Year 25.7% 23.4% 0.26 
 





Table 6: Variables associated with mortality among patients with non-cirrhotic HCC 
 
Variable HR 95% CI p-value 
Age at Diagnosis  1.00 0.99 – 1.01 0.67 
BMI at Diagnosis 0.99 0.96 – 1.01 0.22 
Platelets 1.00 1.00 – 1.00 0.12 
INR 1.96 1.21 – 3.18 0.006 
Albumin 0.65 0.51 – 0.83 <0.001 
AFP 1.00 1.00 – 1.00 <0.001 
Female Sex 1.23 0.92 – 1.66 0.16 
Race 
Asian vs White 0.84 0.37 – 1.95 0.69 
Black vs White 0.80 0.50 – 1.29 0.36 
Hispanic vs White 1.11 0.76 – 1.63 0.58 
Other vs White 1.11 0.58 – 2.14 0.75 
Diabetes 1.20 0.89 – 1.60 0.22 
Anatomic Stage 
Stage II vs Stage I 0.88 0.55 – 1.40 0.58 
Stage III vs Stage I 2.01 1.44 – 2.81 <0.001 
Stage IV vs Stage I 2.12 1.45 – 3.10 <0.001 
Resection 0.24 0.17 – 0.34 <0.001 
Liver Transplantation 0.16 0.05 – 0.53 0.002 
Palliative/Hospice Care 1.85 1.35 – 2.54 <0.001 
Etiologies 
Alcohol Alone vs Unclear/Unknown 1.02 0.64 – 1.63 0.92 
HBV vs Unclear/Unknown 1.60 0.67 – 3.81 0.29 
HCV vs Unclear/Unknown 1.24 0.80 – 1.91 0.33 
NAFLD vs Unclear/Unknown 0.98 0.71 – 1.36 0.92 
 
Abbreviations: BMI: body mass index; INR: international normalized ratio; AFP: Alfa 






Supplemental Table 1 
Characteristics of patients with HCC without underlying cirrhosis, separated based on Level 1 
vs. Level 2 criteria for the absence of cirrhosis 
 
Supplemental Figure 1: 
Study Flow Diagram 
 
Supplemental Figure 2:  
Time Trends of the Percentage of Non-Cirrhotic (Level 1 Criteria)) and  Cirrhotic HCC in the 
Overall Cohort 
Panel A:   
Non-cirrhotic HCC by level 1 criteria: Percentage of non-cirrhotic patients by level 1 criteria from 
2000 to 2014 
Panel B:  
Cirrhotic HCC: Percentage of patients with HCC and underlying cirrhosis over time 
 
 
Supplementary Table 1: Characteristics of patients with HCC without underlying 










Age (Years)  64.1 ± 14.0   63.3 ± 14.1   65.5 ± 13.7  0.06 
Males 400 (66.1%) 264 (66.5%) 136 (65.4%) 0.78 
Race 
- White 420 (70.0%) 279 (71.0%) 141 (68.1%) 
0.52 
- Black 50 (8.3%) 35 (8.9%) 15 (7.2%) 
- Hispanic 59 (9.8%) 33 (8.4%) 26 (12.6%) 
- Asian 46 (7.7%) 29 (7.4%) 17 (8.2%) 
- Other 25 (4.2%) 17 (4.3%) 8 (3.9%) 
BMI (kg/m2)  27.3 ± 6.1   27.4 ± 6.3   27.1 ± 5.9  0.53 
Obesity 134 (22.1%) 85 (21.4%) 49 (23.6%) 0.54 
Diabetes 205 (34.1%) 135 (34.2%) 70 (33.8%) 0.92 
Hypertension 412 (68.4%) 267 (67.6%) 145 (70.0%) 0.53 
Dyslipidemia 229 (38.0%) 155 (39.2%) 74 (35.7%) 0.40 
Coronary Artery Disease 132 (22.0%) 79 (20.1%) 53 (25.6%) 0.11 
Peripheral Vascular Disease 69 (11.5%) 41 (10.4%) 28 (13.6%) 0.24 
History of Alcohol Abuse 102 (17.1%) 61 (15.6%) 41 (19.9%) 0.17 
ALT (units/L)  65.2 ± 82.1   73.2 ± 90.8   50.3 ± 59.6  0.001 
AST (units/L)  88.1 ± 149.0   101.7 ± 180.3   63.2 ± 50.4  0.003 
Total Bilirubin (mg/dL)  1.0 ± 2.0   1.1 ± 2.4   0.9 ± 1.1  0.19 
Alkaline Phosphatase 
(units/L)  178.8 ± 214.0   186.3 ± 247.4   164.7 ± 130.5  0.24 
Albumin (g/dL)  3.9 ± 0.6   3.9 ± 0.6   3.9 ± 0.6  0.65 
Platelets (K/mm3)  278.9 ± 118.9   267.1 ± 116.3   300.8 ± 120.8  0.001 
Creatinine (mg/dL)  1.0 ± 0.7   1.0 ± 0.8   1.1 ± 0.7  0.65 
INR  1.1 ± 0.2   1.1 ± 0.2   1.1 ± 0.3  0.6496 
AFP (ng/mL) 
 27,536.6 ± 
149,888.1  
 28,778.2 ± 
174611.7  
 25,287.5 ± 
89,493.5  0.79 
MELD Score  8.9 ± 3.4   8.9 ± 3.5   8.8 ± 3.2  0.74 
APRI Score  1.0 ± 1.8   1.2 ± 2.2   0.6 ± 0.4  <.0001 
APRI Category 
- <1.0 450 (78.5%) 259 (70.2%) 191 (93.6%) 
<0.001 - 1.0-2.0 77 (13.4%) 67 (18.2%) 10 (4.9%) 
- >2.0 46 (8.0%) 43 (11.7%) 3 (1.5%) 
Performance Status 












- 1 (KPS 70 or 80) 130 (33.7%) 75 (29.3%) 55 (42.3%) 
- 2 (KPS 50 or 60) 48 (12.4%) 31 (12.1%) 17 (13.1%) 
- 3 (KPS 30 or 40) 16 (4.1%) 9 (3.5%) 7 (5.4%) 
- 4 (KPS 10 or 20) 2 (0.5%)  2 (1.5%) 
Underlying liver disease 
- AIH/PBC/PSC 4 (0.7%) 4 (1.0%) 0 (0.0%) 
0.01 
- Alcohol alone 44 (7.3%) 24 (6.0%) 20 (9.6%) 
- HBV + Alcohol 10 (1.7%) 6 (1.5%) 4 (1.9%) 
- HBV alone 50 (8.3%) 34 (8.6%) 16 (7.7%) 
- HC/A1ATD 3 (0.5%) 1 (0.3%) 2 (1.0%) 
- HCV + Alcohol 11 (1.8%) 7 (1.8%) 4 (1.9%) 
- HCV + HBV (+/- alcohol) 10 (1.7%) 6 (1.5%) 4 (1.9%) 
- HCV alone 52 (8.6%) 37 (9.3%) 15 (7.2%) 
- NAFLD 159 (26.3%) 123 (31.0%) 36 (17.3%) 
- Rare etiologies 5 (0.8%) 4 (1.0%) 1 (0.5%) 
- Unclear/Unknown 257 (42.5%) 151 (38.0%) 106 (51.0%) 
Tumor Size  8.9 ± 4.8   8.9 ± 4.9   9.1 ± 4.8  0.61 
Anatomic Stage Category 
- Stage I or II 261 (47.7%) 192 (54.4%) 69 (35.6%) 
<0.001 
- Stage III or IV 286 (52.3%) 161 (45.6%) 125 (64.4%) 
Tumor Differentiation 
- Well 139 (29.8%) 93 (28.6%) 46 (32.6%) 
0.01 
- Moderate 206 (44.2%) 158 (48.6%) 48 (34.0%) 
- Poor 117 (25.1%) 71 (21.8%) 46 (32.6%) 
- Undifferentiated / anaplastic 4 (0.9%) 3 (0.9%) 1 (0.7%) 
Tumor Stage 
- Single 222 (37.0%) 164 (41.3%) 58 (28.6%) 
<0.001 
- 3 tumors < 3 cm 12 (2.0%) 10 (2.5%) 2 (1.0%) 
- Large multinodular 148 (24.7%) 102 (25.7%) 46 (22.7%) 
- Vascular invasion or 
extrahepatic spread 218 (36.3%) 121 (30.5%) 97 (47.8%) 
Tumor within Milan Criteria 90 (14.9%) 74 (18.6%) 16 (7.7%) <0.001 
Overall Survival (Years)  2.5 ± 2.8   3.0 ± 3.1   1.6 ± 1.9  <0.001 
Abbreviations: BMI: body mass index, HIV: human immunodeficiency virus, INR: international 
normalized ratio, MELD: Model for End-Stage Liver Disease, APRI: AST to Platelet Ratio Index, HCV: 
hepatitis C virus, AIH: autoimmune hepatitis. PBC: primary biliary cholangitis, PSC: primary sclerosing 
cholangitis, HC: hemochromatosis, A1ATD: alpha-1-antitrypsin deficiency, NAFLD: non-alcoholic fatty 
liver disease. 
